Submitted by Anonymous (not verified) on 28 September 2023 - 9:42
Human medicines European public assessment report (EPAR): Imatinib Teva, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome;Dermatofibrosarcoma, Date of authorisation: 07/01/2013, Revision: 19, Status: Authorised
Source: